Aicuris, a German pharmaceutical company, has received FDA priority review for pritelivir — a novel helicase-primase inhibitor for the treatment of refractory herpes simplex virus infections in immunocompromised patients.
This is the first new class of HSV treatment to reach regulatory review in decades. Current antivirals — acyclovir, valacyclovir, and famciclovir — have been the standard since the 1980s.
What is pritelivir?
Pritelivir works by blocking the helicase-primase enzyme complex that HSV needs to replicate. That is a different mechanism of action from the existing antivirals, which target the viral DNA polymerase.
Different mechanism means two things:
- It works on strains of HSV that have become resistant to standard treatment
- It may be more effective even against non-resistant strains
What the trials showed
In Phase 3 data, pritelivir showed a 62.7% lesion healing rate compared to 34.0% with standard care in the trial population. That is nearly double the efficacy for the population being studied — immunocompromised patients whose HSV does not respond to standard therapy.
Who is this for?
The current indication is narrow — immunocompromised patients with acyclovir-resistant HSV. That includes people on immunosuppressive therapy after organ transplants, people living with advanced HIV, and some cancer patients.
If approved, pritelivir would not immediately be available for standard recurrent genital or oral herpes. But it opens the door for future trials in broader populations. Successful approval in this first indication would significantly increase the likelihood of broader use later.
What this means for HSV-positive people
The practical impact for most people with recurrent HSV is not immediate. The first approval will be for a specific clinical population. But there are three reasons to pay attention:
- It is the first genuinely new option in 40 years. The HSV field has been stagnant. New classes of drugs mean new possibilities.
- It validates HSV as a research target. For decades, pharma companies have treated HSV as solved. A new drug in the pipeline means more investment to come.
- It may eventually reduce transmission. Current antivirals reduce — but do not eliminate — transmission risk. A more effective antiviral could reduce it further.
What else is in development
Pritelivir is not the only HSV research happening:
- Moderna mRNA-1608 — a therapeutic vaccine for recurrent HSV-2, currently in Phase 1/2 trials
- Yale "prime-and-pull" vaccine — prevented genital herpes infection in preclinical models, published in Science Immunology June 2026
- IM-250 — another helicase-primase inhibitor in earlier trials
The bottom line
HSV treatment is finally moving after four decades of stagnation. Nothing changes for people with recurrent HSV tomorrow. But the pipeline is no longer empty, and that matters.
Haven is a dating and community app built for the HIV+ community in South Africa.
Get Haven on Google Play